All In Biotech

Drug Trial Radar · NCT00446056

Montelukast Post-Marketing Comparative Study With Ketotifen (0476-379)

Montelukast, on Pediatric Bronchial Asthma in Multicenter Comparative Double-Blind Clinical Study (Phase IV) With Ketotifen Fumarate

Last checked: Nov 19, 2026Latest source record: Aug 15, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 188 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

188

Actual

Start

Sep 25, 2003

Primary completion

Jun 16, 2004

Study completion Jun 16, 2004

Sponsor

Lead sponsor
Organon and CoIndustry
Sponsor type
Industry
First posted
Mar 12, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Double
Primary purpose
Treatment
Who can join
All sexes, from 6 years, up to 14 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The clinical study evaluates the safety of montelukast and compares montelukast to ketotifen, used as a control drug, in terms of improvement in morning peak expiratory flow (am pef) over first 2 weeks in patients with pediatric bronchial asthma aged 6 to \< 15. The effect of body weight on the efficacy and safety of montelukast will also be evaluated in this study.

Conditions

  • Asthma

Interventions

  • MK0476, montelukast sodium / Duration of Treatment: 4 WeeksDrug

  • Comparator: ketotifen / Duration of Treatment: 4 WeeksDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Improvement of morning peak expiratory flow over first 2 weeks

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.